GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Scaled Net Operating Assets

argenx SE (XBRU:ARGX) Scaled Net Operating Assets : 0.00 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is argenx SE Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

argenx SE's operating assets for the quarter that ended in Sep. 2024 was €0 Mil. argenx SE's operating liabilities for the quarter that ended in Sep. 2024 was €0 Mil. argenx SE's Total Assets for the quarter that ended in Jun. 2024 was €4,456 Mil. Therefore, argenx SE's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.00.


argenx SE Scaled Net Operating Assets Historical Data

The historical data trend for argenx SE's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Scaled Net Operating Assets Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 -0.18 0.10 0.24 0.29

argenx SE Quarterly Data
Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of argenx SE's Scaled Net Operating Assets

For the Biotechnology subindustry, argenx SE's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where argenx SE's Scaled Net Operating Assets falls into.



argenx SE Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

argenx SE's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(1249.517-389.68)/2958.742
=0.29

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4165.434 - 2915.917
=1249.517

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=408.02 - 14.08 - 4.26
=389.68

argenx SE's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(0-0)/4456.002
=0.00

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0 - 0
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


argenx SE Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of argenx SE's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE Business Description

Industry
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.